

Christoph Hiemke

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8531737/christoph-hiemke-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

395
papers

12,018
citations

52
h-index

91
g-index

430
ext. papers

13,523
ext. citations

3.6
avg, IF

6.1
L-index

#	Paper	IF	Citations
395	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 826138	5	2
394	Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis.. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022 ,	5.5	1
393	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.. <i>Lancet Psychiatry</i> , 2022 , 9, 291-306	23.3	2
392	Tolerability of High-Dose Venlafaxine After Switch From Escitalopram in Nonresponding Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 62-66	1.7	3
391	Pharmakokinetik und Arzneimittelinteraktionen 2021 , 905-920		
390	Therapeutic Reference Ranges for Psychotropic Drugs: A Protocol for Systematic Reviews.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 787043	5	2
389	Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 329-335	6.2	5
388	Buprenorphine-cannabis interaction in patients undergoing opioid maintenance therapy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021 , 271, 847-856	5.1	6
387	Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021 , 271, 1437-1443	5.1	0
386	Predicting the risk of drug-drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study. <i>BMJ Open</i> , 2021 , 11, e045276	3	6
385	Authors' Reply to Suhas et al.: Comment on: "Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation". <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1077-1079	6.2	
384	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. <i>World Journal of Biological Psychiatry</i> , 2021 , 22, 561-628	3.8	3
383	Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1583-1589	6.2	0
382	Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection. <i>Drugs - Real World Outcomes</i> , 2021 , 8, 547-554	2.2	2
381	Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1258-1268	2.6	7
380	Metamizole but not ibuprofen reduces the plasma concentration of sertraline: Implications for the concurrent treatment of pain and depression/anxiety disorders. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1111-1119	3.8	2
379	Potentially inappropriate medication in older psychiatric patients. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 331-339	2.8	5

378	Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample. <i>Pharmacopsychiatry</i> , 2021 , 54, 31-35	2	1
377	Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients. <i>Journal of Neural Transmission</i> , 2021 , 128, 243-252	4.3	4
376	Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 79-102	3.2	9
375	Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. <i>Journal of Psychopharmacology</i> , 2021 , 35, 273-278	4.6	2
374	Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders. <i>PLoS ONE</i> , 2021 , 16, e0255192	3.7	2
373	Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients. <i>Journal of Neural Transmission</i> , 2021 , 128, 263-272	4.3	5
372	The interactions between COVID-19 drugs and psychotropic agents. <i>European Psychiatry</i> , 2021 , 64, S15-S15		
371	P.0911 Drug monitoring of aripiprazole, dehydroaripiprazole and the active moiety: A systematic review on the therapeutic reference range. <i>European Neuropsychopharmacology</i> , 2021 , 53, S670	1.2	
370	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , 2021 , 55,	2	11
369	P.0693 Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range. <i>European Neuropsychopharmacology</i> , 2021 , 53, S507-S508	1.2	
368	Prevalence and sort of pharmacokinetic drug-drug interactions in hospitalized psychiatric patients. <i>Journal of Neural Transmission</i> , 2020 , 127, 1185-1198	4.3	8
367	Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine. <i>Frontiers in Psychiatry</i> , 2020 , 11, 32	5	0
366	Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020 , 127, 303-308	3.1	2
365	Safety of Psychotropic Medications in People With COVID-19: Evidence Review and Practical Recommendations. <i>Focus (American Psychiatric Publishing)</i> , 2020 , 18, 466-481	1.1	2
364	Pharmacokinetic and Pharmacodynamic Principles 2020 , 1-19		
363	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	39
362	Adverse Drug Reactions, Intoxications and Interactions of Neuropsychotropic Medications 2020 , 1-53		
361	The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism. <i>Pharmacopsychiatry</i> , 2020 , 53, 65-70	2	1

360	Dose-Related Concentrations of Neuroactive/Psychoactive Drugs Expected in Blood of Children and Adolescents. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 315-324	3.2	4
359	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020 , 18, 215	11.4	30
358	Guía de consenso de expertos para la monitorización terapéutica de drogas en neuropsicofarmacología. <i>Psiquiatría Biológica</i> , 2020 , 27, 83-95	0.2	0
357	Methylphenidate challenge test in adults with attention deficit/hyperactivity disorder (ADHD): Clinical effects and their predictors. <i>Human Psychopharmacology</i> , 2020 , 35, e2740	2.3	
356	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 1109-1116	2.8	6
355	Pharmacokinetic correlates of venlafaxine: associated adverse reactions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019 , 269, 851-857	5.1	4
354	A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 603-621	3.8	41
353	Pharmakokinetik und Arzneimittelinteraktionen 2019 , 991-1005		
352	Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. <i>International Clinical Psychopharmacology</i> , 2019 , 34, 241-246	2.2	3
351	Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 550-560	1.7	6
350	Concentration-Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 174-179	3.2	21
349	Non-adherence to psychotropic medication assessed by plasma level in newly admitted psychiatric patients: Prevalence before acute admission. <i>Psychiatry and Clinical Neurosciences</i> , 2019 , 73, 175-178	6.2	5
348	Therapeutic Drug Monitoring of Naltrexone and 6-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges. <i>Alcohol and Alcoholism</i> , 2019 , 54, 51-55	3.5	2
347	QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients. <i>Pharmacopsychiatry</i> , 2019 , 52, 38-43	2	12
346	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 162-174	3.8	64
345	Reduced clearance of venlafaxine in a combined treatment with quetiapine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 85, 116-121	5.5	15
344	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. <i>Pharmacopsychiatry</i> , 2018 , 51, 9-62	2	473
343	Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients: Therapeutic Drug Monitoring Uncovers the Impact on Drug Metabolism. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	10

342	Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 729-737	6.2	10
341	Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. <i>Journal of Affective Disorders</i> , 2018 , 227, 506-511	6.6	12
340	Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations. <i>European Neuropsychopharmacology</i> , 2018 , 28, 130-137	1.2	16
339	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 1237-1253	3.8	26
338	Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , 2018 , 33, 322-329	2.2	7
337	A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 625-639	3.8	26
336	Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1668-1675	3.8	10
335	Making the Case for Power Abuse Disorder as a Nosologic Entity. <i>Pharmacology</i> , 2017 , 100, 50-63	2.3	2
334	First-Episode Psychosis Possibly due to Roxithromycin-Related Inhibition of Metabolization of Tetrahydrocannabinol. <i>Journal of Clinical Psychopharmacology</i> , 2017 , 37, 369-370	1.7	2
333	Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017 , 76, 101-106	5.5	6
332	Effect of smoking on risperidone pharmacokinetics - A multifactorial approach to better predict the influence on drug metabolism. <i>Schizophrenia Research</i> , 2017 , 185, 51-57	3.6	17
331	Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. <i>Journal of Substance Abuse Treatment</i> , 2017 , 74, 7-15	4.2	2
330	Drug safety related to agents used for opioid maintenance therapy. <i>European Psychiatry</i> , 2017 , 41, s870-6870		
329	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 965-981	3.8	41
328	Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017 , 267, 325-333	5.1	10
327	Pharmakokinetik und Arzneimittelinteraktionen 2017 , 938-951		1
326	Therapeutisches Drug Monitoring 2017 , 187-201		
325	Pharmakotherapie bei Alterspatienten 2017 , 121-139		

324	Therapeutisches Drugmonitoring in der Psychiatrie 2017 , 671-684		
323	hs-CRP Predicts Improvement in Depression in Patients With Type 1 Diabetes and Major Depression Undergoing Depression Treatment: Results From the Diabetes and Depression (DAD) Study. <i>Diabetes Care</i> , 2016 , 39, e171-3	14.6	11
322	Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. <i>Psychoneuroendocrinology</i> , 2016 , 73, 9-15	5	23
321	Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2016 , 36, 554-561	1.7	23
320	Drug-Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Using Different MedDRA Terms. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 769-78	2.9	9
319	Consensus guideline for therapeutic drug monitoring in psychiatry (2004): Bibliometric analysis of citations for the period 2004-2011. <i>Nordic Journal of Psychiatry</i> , 2016 , 70, 202-7	2.3	
318	Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 407-22	5.5	56
317	Monitoring of Plasma Concentrations of Psychotropic Drugs in Pharmacovigilance 2016 , 95-119		
316	Duloxetine enters the brain - But why is it not found in the cerebrospinal fluid. <i>Journal of Affective Disorders</i> , 2016 , 189, 159-63	6.6	7
315	Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology. <i>Current Drug Delivery</i> , 2016 , 13, 353-61	3.2	16
314	Therapeutisches Drugmonitoring in der Psychiatrie 2016 , 1-15		
313	Measuring citalopram in blood and cerebrospinal fluid: revealing a distribution pattern that differs from other antidepressants. <i>International Clinical Psychopharmacology</i> , 2016 , 31, 119-26	2.2	7
312	Pharmacokinetic patterns of risperidone-associated adverse drug reactions. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1091-8	2.8	24
311	Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?. <i>International Clinical Psychopharmacology</i> , 2016 , 31, 259-64	2.2	19
310	Amphiphilic Copolymers Shuttle Drugs Across the Blood-Brain Barrier. <i>Macromolecular Bioscience</i> , 2016 , 16, 655-65	5.5	7
309	Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. <i>Psychopharmacology</i> , 2016 , 233, 1695-705	4.7	43
308	Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial. <i>European Neuropsychopharmacology</i> , 2016 , 26, 705-16	1.2	30
307	Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI. <i>Journal of Neural Transmission</i> , 2015 , 122, 721-9	4.3	22

306	Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment. <i>Journal of Affective Disorders</i> , 2015 , 175, 199-208	6.6	5
305	Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. <i>Psychiatry Research</i> , 2015 , 229, 257-63	9.9	10
304	Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study: A Randomized Controlled Multicenter Trial. <i>Diabetes Care</i> , 2015 , 38, 767-75	14.6	44
303	Distribution pattern of mirtazapine and normirtazapine in blood and CSF. <i>Psychopharmacology</i> , 2015 , 232, 807-13	4.7	9
302	Retrospective pilot study for analysis of antidepressant serum concentrations of citalopram and venlafaxine during inflammation. <i>Pharmacopsychiatry</i> , 2015 , 48, 215-8	2	6
301	Elevated risperidone serum concentrations during acute inflammation, two cases. <i>International Journal of Psychiatry in Medicine</i> , 2015 , 50, 335-44	1	18
300	Lamotrigine in pregnancy - therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. <i>International Clinical Psychopharmacology</i> , 2015 , 30, 249-54	2.2	9
299	Ist die Genotypisierung von CYP-Enzymen sinnvoll?. <i>Der Neurologe Und Psychiater</i> , 2015 , 16, 16-17	0	
298	Therapeutic drug monitoring for patients with Alzheimer dementia to improve treatment with donepezil. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 353-61	3.2	18
297	Risk of bleeding related to selective and non-selective serotonergic antidepressants: a case/non-case approach using data from two pharmacovigilance databases. <i>Pharmacopsychiatry</i> , 2015 , 48, 19-24	2	9
296	Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey. <i>Journal of Neural Transmission</i> , 2015 , 122, 1609-17	4.3	10
295	Side effects related to potentially inappropriate medications in elderly psychiatric patients under everyday pharmacotherapy. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 165-72	2.8	17
294	Prevalence and type of potential pharmacokinetic drug-drug interactions in old aged psychiatric patients 2015 , 1, 3-10		3
293	Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, 25-31	4.6	12
292	Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 254-7	6.1	42
291	Abuse of methylphenidate in Germany: data from spontaneous reports of adverse drug reactions. <i>Psychiatry Research</i> , 2014 , 215, 252-4	9.9	22
290	Evaluation of P-glycoprotein (abcb1a/b) modulation of [(18)F]fallypride in MicroPET imaging studies. <i>Neuropharmacology</i> , 2014 , 84, 152-8	5.5	9
289	Severe adverse drug events under combination of nortriptyline and melperone due to pharmacokinetic interaction. <i>Journal of Clinical Psychopharmacology</i> , 2014 , 34, 394-6	1.7	6

288	Influence of concomitant medications on the total clearance and the risk for supra-therapeutic plasma concentrations of Citalopram. A population-based cohort study. <i>Pharmacopsychiatry</i> , 2014 , 47, 239-44	2	7
287	Increased CSF APPs- β levels in patients with Alzheimer disease treated with acitretin. <i>Neurology</i> , 2014 , 83, 1930-5	6.5	78
286	Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 473-9	3.2	23
285	Therapeutic drug monitoring of zuclopenthixol in a double-blind placebo-controlled discontinuation study in adults with intellectual disabilities and aggressive behaviour. <i>Pharmacopsychiatry</i> , 2014 , 47, 29-32	2	3
284	Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring. <i>Pharmacopsychiatry</i> , 2014 , 47, 174-9	2	12
283	Pregabalin abuse and dependence in Germany: results from a database query. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 1335-42	2.8	79
282	The "DGPPN-Cohort": A national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 695-701	5.1	10
281	Study protocol of the Diabetes and Depression Study (DAD): a multi-center randomized controlled trial to compare the efficacy of a diabetes-specific cognitive behavioral group therapy versus sertraline in patients with major depression and poorly controlled diabetes mellitus. <i>BMC Psychiatry</i> , 2013 , 13, 206	4.2	16
280	Effects of antipsychotic treatment on cognition in healthy subjects. <i>Journal of Psychopharmacology</i> , 2013 , 27, 374-85	4.6	23
279	Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1636-44	1.2	29
278	Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties. <i>Pharmacopsychiatry</i> , 2013 , 46, 175-80	2	5
277	Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. <i>Pharmacopsychiatry</i> , 2013 , 46, 214-20	2	23
276	Quetiapine and norquetiapine serum concentrations and clinical effects in depressed patients under augmentation therapy with quetiapine. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 539-45	3.2	4
275	Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopram. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 396-401	3.2	18
274	Non-fatal and fatal liver failure associated with valproic acid. <i>Pharmacopsychiatry</i> , 2013 , 46, 63-8	2	24
273	Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 279-82	3.2	14
272	Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression. <i>Pharmacopsychiatry</i> , 2013 , 46, 261-6	2	15
271	Abuse liability of flupirtine revisited: implications of spontaneous reports of adverse drug reactions. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 1328-33	2.9	6

270	The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy. <i>International Review of Psychiatry</i> , 2013 , 25, 494-508	3.6	16
269	Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. <i>Current Drug Delivery</i> , 2013 , 10, 46-53	3.2	15
268	Behavioural consequences of p-glycoprotein deficiency in mice, with special focus on stress-related mechanisms. <i>Journal of Neuroendocrinology</i> , 2012 , 24, 809-17	3.8	9
267	In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. <i>Pharmacology Biochemistry and Behavior</i> , 2012 , 102, 312-20	3.9	22
266	Interactions and monitoring of antipsychotic drugs. <i>Handbook of Experimental Pharmacology</i> , 2012 , 241-65	3.5	14
265	Central Nervous System Drugs 2012 , 301-329		1
264	P.2.b.009 Regulation of the astrocytic proteins NDRG2 and GFAP in the rat hippocampus by chronic social stress: no reversal by citalopram. <i>European Neuropsychopharmacology</i> , 2012 , 22, S246	1.2	
263	Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. <i>Neuropharmacology</i> , 2012 , 62, 264-9	5.5	52
262	Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus. <i>Psychopharmacology</i> , 2012 , 224, 209-22	4.7	69
261	Desomorphine goes "crocodile". <i>Journal of Addictive Diseases</i> , 2012 , 31, 407-12	1.7	31
260	"Krokodil": revival of an old drug with new problems. <i>Substance Use and Misuse</i> , 2012 , 47, 861-3	2.2	19
259	Flupentixol: relevance of stereoselective therapeutic drug monitoring. <i>Psychopharmacology</i> , 2012 , 221, 719-20	4.7	1
258	Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein. <i>Neurodegenerative Diseases</i> , 2012 , 10, 224-8	2.3	29
257	The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. <i>Pharmacopsychiatry</i> , 2012 , 45, 229-35	2	27
256	The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression. <i>Pharmacopsychiatry</i> , 2012 , 45, 108-13	2	16
255	Therapeutic drug monitoring for antidepressant drug treatment. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5818-27	3.3	33
254	Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. <i>International Clinical Psychopharmacology</i> , 2012 , 27, 61-8	2.2	36
253	High venlafaxine serum levels after prior fluoxetine medication. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 295-7	1.7	2

252	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring 2012 , 441-464		4
251	Krokodil – eine neue Droge?. <i>Nervenheilkunde</i> , 2012 , 31, 69-72	0.3	5
250	Liver failure under valproic acid. <i>European Psychiatry</i> , 2011 , 26, 1282-1282		6
249	The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: a pilot study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011 , 35, 415-20	5.5	58
248	Association between citalopram serum levels and clinical improvement of patients with major depression. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 281-6	1.7	22
247	Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 561-72	3.2	20
246	Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. <i>Psychopharmacology</i> , 2011 , 215, 367-77	4.7	22
245	Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters. <i>Psychopharmacology</i> , 2011 , 217, 289-95	4.7	7
244	"There is no dose-response relationship in psychopharmacotherapy" vs "pharmacotherapy in psychiatry is based on ligand-receptor interaction": a unifying hypothesis and the need for plasma concentration based clinical trials. <i>Psychopharmacology</i> , 2011 , 217, 297-300	4.7	10
243	Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. <i>Psychopharmacology</i> , 2011 , 218, 733-48	4.7	11
242	HPMA based amphiphilic copolymers mediate central nervous effects of domperidone. <i>Macromolecular Rapid Communications</i> , 2011 , 32, 712-7	4.8	29
241	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. <i>Pharmacopsychiatry</i> , 2011 , 44, 195-235	2	641
240	Therapeutic drug monitoring in psychiatry. <i>Pharmacopsychiatry</i> , 2011 , 44, 193-4		2
239	Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. <i>Pharmacopsychiatry</i> , 2011 , 44, 55-9	2	15
238	P-glycoprotein influence on the brain uptake of a 5-HT(2A) ligand: [(18)F]MH.MZ. <i>Neuropsychobiology</i> , 2011 , 63, 183-90	4	4
237	Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. <i>Pharmacopsychiatry</i> , 2011 , 44, 236-48	2	39
236	Therapeutic drug monitoring in Italian psychiatry. <i>Pharmacopsychiatry</i> , 2011 , 44, 259-62		2
235	AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. <i>Pharmacopsychiatry</i> , 2011 , 44, 195-235	2	4

234	French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs. <i>Fundamental and Clinical Pharmacology</i> , 2010 , 24, 377-84	3.1	10
233	Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice. <i>Pharmaceutics</i> , 2010 , 2, 258-274	6.4	8
232	SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents in the Drug Prescription Information. <i>International Journal of Knowledge Discovery in Bioinformatics</i> , 2010 , 1, 1-11		
231	Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 951-60	5.8	29
230	Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 30, 245-53	2.6	7
229	Spatial learning and expression patterns of PP1 mRNA in mouse hippocampus. <i>Neuropsychobiology</i> , 2010 , 61, 188-96	4	13
228	Low novelty seeking and high self directedness scores in alcohol-dependent patients without comorbid psychiatric disorders homozygous for the A10 allele of the dopamine transporter gene. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 382-389	3.8	11
227	Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. <i>Neuropharmacology</i> , 2010 , 59, 474-9	5.5	35
226	Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. <i>European Neuropsychopharmacology</i> , 2010 , 20, 632-40	1.2	34
225	Aripiprazole in pregnancy and lactation: a case report. <i>Journal of Clinical Psychopharmacology</i> , 2010 , 30, 204-5	1.7	33
224	Determination of naltrexone and 6beta-naltrexol in human blood: comparison of high-performance liquid chromatography with spectrophotometric and tandem-mass-spectrometric detection. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 396, 1249-57	4.4	6
223	Serum concentrations of paliperidone versus risperidone and clinical effects. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 797-803	2.8	33
222	A common mechanism of action of the selective serotonin reuptake inhibitors citalopram and fluoxetine: reversal of chronic psychosocial stress-induced increase in CRE/CREB-directed gene transcription in transgenic reporter gene mice. <i>European Journal of Pharmacology</i> , 2010 , 633, 33-8	5.3	20
221	Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers. <i>Human Psychopharmacology</i> , 2010 , 25, 472-80	2.3	17
220	Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial. <i>Trials</i> , 2010 , 11, 21	2.8	24
219	Interaktionen 2010 , 405-423		0
218	Low novelty seeking and high self directedness scores in alcohol-dependent patients without comorbid psychiatric disorders homozygous for the A10 allele of the dopamine transporter gene. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 382-9	3.8	7
217	Pharmakokinetik 2010 , 289-351		

216	Rotarod impairment: catalepsy-like screening test for antipsychotic side effects. <i>International Journal of Neuroscience</i> , 2009 , 119, 1509-22	2	16
215	Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey. <i>Pharmacopsychiatry</i> , 2009 , 42, 189-93	2	23
214	Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. <i>Journal of Psychopharmacology</i> , 2009 , 23, 278-86	4.6	16
213	Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. <i>Journal of Neuroscience Research</i> , 2009 , 87, 2551-60	4.4	40
212	Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. <i>Psychopharmacology</i> , 2009 , 202, 579-87	4.7	15
211	Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study. <i>Psychopharmacology</i> , 2009 , 207, 213-23	4.7	16
210	Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene. <i>Clinical Biochemistry</i> , 2009 , 42, 1282-90	3.5	13
209	Analysis of Multiple Antidepressant and Antipsychotic Drugs Including Active Metabolites in Serum of Psychiatric Patients by LC with Column Switching and Spectrophotometric Detection. <i>Chromatographia</i> , 2009 , 69, 821-827	2.1	15
208	Determination of Drug Concentrations in Serum and Dopamine Receptor Occupancy in Brain for Optimal Antipsychotic Drug Therapy. <i>European Psychiatry</i> , 2009 , 24, 1-1	6	
207	The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. <i>European Psychiatry</i> , 2009 , 24, 143-8	6	10
206	High mirtazapine plasma levels in infant after breast feeding: case report and review of the literature. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 191-2	1.7	16
205	Toxic clozapine serum levels during inflammatory reactions. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 392-4	1.7	35
204	Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 1431-2	5.8	13
203	Low concentration of ziprasidone in human milk: a case report. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 437-8	5.8	12
202	No effect of six weeks of treatment with escitalopram on mood in healthy volunteers--irrespective of genotype for the promoter of the serotonin transporter. <i>Psychiatry Research</i> , 2008 , 161, 339-43	9.9	6
201	Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. <i>Behavioural Brain Research</i> , 2008 , 188, 298-303	3.4	49
200	Hormonal influences on cardiovascular norepinephrine transporter responses in healthy women. <i>Hypertension</i> , 2008 , 51, 1203-9	8.5	26
199	Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgenic reporter gene mice. <i>Neuropsychopharmacology</i> , 2008 , 33, 2407-15	8.7	32

198	No influence of dialysis on mirtazapine - a case report. <i>Pharmacopsychiatry</i> , 2008 , 41, 259-60	2	6
197	Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. <i>American Journal of Psychiatry</i> , 2008 , 165, 988-95	11.9	119
196	Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. <i>World Journal of Biological Psychiatry</i> , 2008 , 9, 212-8	3.8	69
195	Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 608-17	1.7	33
194	Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam. <i>Behavioural Pharmacology</i> , 2008 , 19, 183-96	2.4	84
193	Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 159-66	2.8	45
192	Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258 Suppl 1, 21-7	5.1	31
191	LC with Column-Switching and Spectrophotometric Detection for Determination of Risperidone and 9-Hydroxyrisperidone in Human Serum. <i>Chromatographia</i> , 2008 , 67, 321-324	2.1	21
190	Spezielle Arzneimittelinteraktionen 2008 , 1127-1144		2
189	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring 2008 , 375-397		1
188	Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 462-6	3.2	23
187	Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. <i>Neuropsychopharmacology</i> , 2007 , 32, 1490-503	8.7	265
186	Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 848, 391-4	3.2	46
185	Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2007 , 41, 673-9	5.2	35
184	Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence. <i>Pharmacopsychiatry</i> , 2007 , 40, 121-7	2	19
183	Therapeutic drug monitoring-based clozapine dosing recommendations. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 130-1	3.2	4
182	Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 767-72	3.2	17
181	Aripiprazole in human milk. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10, 433	5.8	14

180	Effect of chronic citalopram on serotonin-related and stress-regulated genes in the dorsal raphe nucleus of the rat. <i>European Neuropsychopharmacology</i> , 2007 , 17, 417-29	1.2	53
179	Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. <i>World Journal of Biological Psychiatry</i> , 2007 , 8, 123-6	3.8	41
178	Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2007 , 45, 36-46	2	10
177	Therapeutic drug monitoring of antidepressants [Clinical aspects] 2007 , 261-267		9
176	IAC, ein Programm zur praktischen Handhabung von Arzneimittelwechselwirkungen in der Psychiatrie. <i>Psychosomatik Und Konsiliarpsychiatrie</i> , 2006 , 1, 56-58		1
175	Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. <i>Psychoneuroendocrinology</i> , 2006 , 31, 256-64	5	60
174	Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. <i>Pharmacopsychiatry</i> , 2006 , 39, 41-6	2	20
173	The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. <i>Neuropsychopharmacology</i> , 2006 , 31, 1027-35	8.7	86
172	Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. <i>Neuropsychopharmacology</i> , 2006 , 31, 1616-26	8.7	317
171	Effects of fluoxetine on behavioral deficits evoked by chronic social stress in rats. <i>Behavioural Brain Research</i> , 2006 , 174, 188-92	3.4	89
170	Over-expression of two different forms of the alpha-secretase ADAM10 affects learning and memory in mice. <i>Behavioural Brain Research</i> , 2006 , 175, 278-84	3.4	39
169	Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats. <i>Behavioural Pharmacology</i> , 2006 , 17, 19-29	2.4	87
168	Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 671-3	1.7	14
167	Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 83-8	3.2	39
166	Clinical relevance of TDM of SSRIs. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 716-7; author reply 717	3.2	5
165	Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 830, 342-8	3.2	58
164	CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006 , 31, 493-502	2.2	183
163	Region specific distribution of levomepromazine in the human brain. <i>Journal of Neural Transmission</i> , 2006 , 113, 387-97	4.3	20

162	Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). <i>Journal of Neural Transmission</i> , 2006 , 113, 787-801	4.3	46
161	The TPH intron 7 A218C polymorphism and TCI dimension scores in alcohol-dependent patients: hints to nonspecific psychopathology. <i>Addictive Behaviors</i> , 2005 , 30, 1135-43	4.2	14
160	Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 158-62	3.2	20
159	Tyrosine hydroxylase Val-81-Met polymorphism associated with early-onset alcoholism. <i>Psychiatric Genetics</i> , 2005 , 15, 13-6	2.9	18
158	Paroxetine serum concentrations in depressed patients and response to treatment. <i>Pharmacopsychiatry</i> , 2005 , 38, 118-21	2	26
157	Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. <i>Pharmacopsychiatry</i> , 2005 , 38, 113-7	2	26
156	Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. <i>Clinical Chemistry</i> , 2005 , 51, 1718-21	5.5	64
155	Therapeutisches Drugmonitoring zur Therapieoptimierung 2005 , 173-184		
154	The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. <i>Dialogues in Clinical Neuroscience</i> , 2005 , 7, 231-47	5.7	38
153	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. <i>Journal of Pharmacy and Pharmacology</i> , 2004 , 56, 967-75	4.8	114
152	Reduction of clozapine-induced hypersalivation by pirenzepine is safe. <i>Pharmacopsychiatry</i> , 2004 , 37, 43-5	2	24
151	The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. <i>Pharmacopsychiatry</i> , 2004 , 37, 243-65	2	399
150	Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs. <i>Laboratoriums Medizin</i> , 2004 , 28, 326-333		
149	Population pharmacokinetic analysis of mirtazapine. <i>European Journal of Clinical Pharmacology</i> , 2004 , 60, 473-80	2.8	31
148	Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. <i>European Journal of Clinical Pharmacology</i> , 2004 , 60, 329-36	2.8	124
147	A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. <i>Journal of Clinical Investigation</i> , 2004 , 113, 1456-64	15.9	438
146	Elevated quetiapine serum concentrations in a patient treated concomitantly with doxepin, lorazepam, and pantoprazole. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 568-71	1.7	4
145	High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2004 , 7, 421-30	5.8	43

144	Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 78-84	3.2	23
143	Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 459-61	3.2	35
142	Therapeutic monitoring of new antipsychotic drugs. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 156-60	3.2	92
141	What the clinician still has to be reminded of. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 582	3.2	11
140	Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 167-70	3.2	37
139	How does the benzamide antipsychotic amisulpride get into the brain?--An in vitro approach comparing amisulpride with clozapine. <i>Neuropsychopharmacology</i> , 2003 , 28, 1916-22	8.7	33
138	Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions?. <i>Pharmacopsychiatry</i> , 2003 , 36, 98-104	2	55
137	Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. <i>Pharmacopsychiatry</i> , 2003 , 36, 3-6	2	26
136	Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 784, 405-10	3.2	34
135	Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. <i>Journal of Nuclear Medicine</i> , 2003 , 44, 109-16	8.9	35
134	New dopamine D2 receptor polymorphisms in rats and association with apomorphine-induced stereotypies. <i>Brain Research</i> , 2002 , 926, 1-9	3.7	5
133	Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. <i>Journal of Neural Transmission</i> , 2002 , 109, 871-80	4.3	30
132	Free-Choice Ethanol Consumption Under the Influence of GABAergic Drugs in Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2002 , 26, 457-462	3.7	21
131	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. <i>Pharmaceutical Research</i> , 2002 , 19, 1034-7	4.5	21
130	Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. <i>Neuropsychobiology</i> , 2002 , 46, 33-40	4	23
129	Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 502-6	1.7	55
128	The chronic psychosocial stress paradigm in male tree shrews: evaluation of a novel animal model for depressive disorders. <i>Stress</i> , 2002 , 5, 37-46	3	76
127	Tiagabine, a gamma-amino-butyric acid transporter inhibitor impairs spatial learning of rats in the Morris water-maze. <i>Behavioural Brain Research</i> , 2002 , 133, 391-4	3.4	31

126	Detection of TOAD-64 in adult rat brain as revealed by two-dimensional protein gel electrophoresis followed by MALDI mass spectrometry possible modulatory effect of chronic haloperidol treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002 , 26, 693-8	5.5	3
125	Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine. <i>Neuroscience Letters</i> , 2002 , 330, 231-4	3.3	64
124	Serotonin-selektive Antidepressiva(SSRI, DSA) 2002 , 223-363		
123	Therapeutisches Drug-Monitoring von Antidepressiva 2002 , 911-922		3
122	Free-Choice Ethanol Consumption Under the Influence of GABAergic Drugs in Rats 2002 , 26, 457		1
121	Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 440-1	1.7	33
120	Free-choice ethanol consumption under the influence of GABAergic drugs in rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2002 , 26, 457-62	3.7	12
119	Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. <i>Biomedical Applications</i> , 2001 , 759, 63-71		48
118	Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. <i>Pharmacopsychiatry</i> , 2001 , 34, 27-32	2	12
117	Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. <i>Schizophrenia Research</i> , 2001 , 49, 223-5	3.6	33
116	Behavioral analysis indicates benzodiazepine-tolerance mediated by the benzodiazepine binding-site at the GABA(A)-receptor. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001 , 25, 1145-60	5.5	7
115	Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001 , 25, 965-82	5.5	40
114	Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 167-74	1.7	53
113	Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 410-3	3.2	63
112	Kann der pharmakologisch aktive N-demethylierte Metabolit von Clozapin die Blut-Hirn-Schranke durchdringen? 2001 , 123-126		
111	Auftreten von Nebenwirkungen unter Clozapin-Fluvoxamin-Kombination 2001 , 133-138		
110	Sex differences in allelic frequencies of the 5-HT _{2C} Cys23Ser polymorphism in psychiatric patients and healthy volunteers: findings from an association study. <i>Psychiatric Genetics</i> , 2000 , 10, 59-65	2.9	31
109	Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. <i>Biomedical Applications</i> , 2000 , 740, 135-40		34

108	Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers. <i>Psychoneuroendocrinology</i> , 2000 , 25, 377-88	5	19
107	Diazepam has no beneficial effects on stress-induced behavioural and endocrine changes in male tree shrews. <i>Pharmacology Biochemistry and Behavior</i> , 2000 , 65, 539-46	3.9	42
106	Behavioral effects of GABA(A) receptor stimulation and GABA-transporter inhibition. <i>Pharmacology Biochemistry and Behavior</i> , 2000 , 65, 351-6	3.9	10
105	Pharmacokinetics of selective serotonin reuptake inhibitors 2000 , 85, 11-28		568
104	Increased bioavailability of oral melatonin after fluvoxamine coadministration. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 1-6	6.1	70
103	Adenylyl cyclase activity is increased in younger, but decreased in older, alcoholic patients after detoxification. <i>Alcohol and Alcoholism</i> , 2000 , 35, 249-54	3.5	4
102	Fluvoxamine strongly inhibits melatonin metabolism in a patient with low-amplitude melatonin profile. <i>Archives of General Psychiatry</i> , 2000 , 57, 812-3		9
101	The HTR1B 861G>C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy. <i>Psychiatry Research</i> , 2000 , 97, 1-10	9.9	68
100	Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. <i>European Neuropsychopharmacology</i> , 2000 , 10, 401-5	1.2	29
99	Increase in serum clomipramine concentrations caused by valproate. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 493-4	1.7	25
98	Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. <i>Pharmacopsychiatry</i> , 1999 , 32, 148-53	2	63
97	Coadministration of clozapine and fluvoxamine in psychotic patients--clinical experience. <i>Pharmacopsychiatry</i> , 1999 , 32, 76-7	2	40
96	Chronic oral haloperidol and clozapine in rats: A behavioral evaluation. <i>Neuropsychobiology</i> , 1999 , 39, 86-91	4	22
95	Fishing for a drug: solid-phase microextraction for the assay of clozapine in human plasma. <i>Biomedical Applications</i> , 1999 , 731, 231-40		27
94	Chronic psychosocial stress and antidepressant treatment in tree shrews: time-dependent behavioral and endocrine effects. <i>Neuroscience and Biobehavioral Reviews</i> , 1999 , 23, 937-47	9	67
93	Rapid cloning of cDNA ends polymerase chain reaction of G-protein-coupled receptor kinase 6: an improved method to determine 5P and 3PcDNA ends. <i>Brain Research Protocols</i> , 1999 , 3, 242-51		1
92	Quantitation of GABA transporter 3 (GAT3) mRNA in rat brain by competitive RT-PCR. <i>Brain Research Protocols</i> , 1999 , 4, 341-50		7
91	Day- and night-time contents of monoamines and their metabolites in the medial preoptic area of the rat hypothalamus. <i>Neuroscience Letters</i> , 1999 , 266, 29-32	3.3	11

90	Distribution of clozapine and desmethylclozapine between blood and brain in rats. <i>European Neuropsychopharmacology</i> , 1999 , 9, 253-6	1.2	52
89	Blood ethanol levels and adenylyl cyclase activity in lymphocytes of alcoholic patients. <i>Biological Psychiatry</i> , 1999 , 45, 489-93	7.9	11
88	Neuroendocrine response to antipsychotics: effects of drug type and gender. <i>Biological Psychiatry</i> , 1999 , 45, 89-97	7.9	57
87	Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. <i>Behavioural Pharmacology</i> , 1999 , 10, 131-7	2.4	33
86	Oxybutynin enhances the metabolism of clomipramine and dextrorphan possibly by induction of a cytochrome P450 isoenzyme. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 287-9	1.7	8
85	Activity of the Adenylyl Cyclase in Lymphocytes of Male Alcoholic Patients Is State Dependent. <i>Alcoholism: Clinical and Experimental Research</i> , 1998 , 22, 2073-2079	3.7	2
84	Strain differences in open-field and elevated plus-maze behavior of rats without and with pretest handling. <i>Pharmacology Biochemistry and Behavior</i> , 1998 , 59, 807-11	3.9	124
83	Inhibition of dextromethorphan metabolism by moclobemide. <i>Psychopharmacology</i> , 1998 , 135, 22-6	4.7	20
82	Automated determination of clomipramine and its major metabolites in human and rat serum by high-performance liquid chromatography with on-line column-switching. <i>Biomedical Applications</i> , 1998 , 710, 227-33		26
81	Combination of open field and elevated plus-maze: a suitable test battery to assess strain as well as treatment differences in rat behavior. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1998 , 22, 1197-215	5.5	65
80	Chronical haloperidol and clozapine treatment in rats: differential RNA display analysis, behavioral studies and serum level determination. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1998 , 22, 1129-39	5.5	10
79	Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. <i>European Neuropsychopharmacology</i> , 1998 , 8, 315-20	1.2	14
78	Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. <i>Pharmacopsychiatry</i> , 1998 , 31, 199-200	2	20
77	Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. <i>Pharmacopsychiatry</i> , 1998 , 31, 117-21	2	24
76	Effects of pulsed high-frequency electromagnetic fields on the neuroendocrine system. <i>Neuroendocrinology</i> , 1998 , 67, 139-44	5.6	60
75	Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 2-9	1.7	120
74	Nonlinear pharmacokinetics of fluvoxamine and gender differences. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 446-9	3.2	56
73	Interaction of modafinil and clomipramine as comedication in a narcoleptic patient. <i>Clinical Neuropharmacology</i> , 1998 , 21, 127-9	1.4	7

72	Activity of the adenylyl cyclase in lymphocytes of male alcoholic patients is state dependent. <i>Alcoholism: Clinical and Experimental Research</i> , 1998 , 22, 2073-9	3.7	
71	Monitoring serum concentrations of clomipramine and metabolites: fluorescence polarization immunoassay versus high performance liquid chromatography. <i>Pharmacopsychiatry</i> , 1997 , 30, 128-32	2	18
70	CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 453-61		34
69	[123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects. <i>Psychiatry Research - Neuroimaging</i> , 1997 , 75, 103-14	2.9	8
68	Stimulation of immediate early gene expression by desipramine in rat brain. <i>Biological Psychiatry</i> , 1997 , 42, 317-23	7.9	34
67	Molecular cloning of rat G-protein-coupled receptor kinase 6 (GRK6) from brain tissue, and its mRNA expression in different brain regions and peripheral tissues. <i>Molecular Brain Research</i> , 1997 , 49, 278-82		11
66	Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. <i>Psychopharmacology</i> , 1997 , 131, 19-22	4.7	11
65	Automated determination of clozapine and major metabolites in serum and urine. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 480-8	3.2	24
64	Interaktionen von Clozapin mit anderen Psychopharmaka 1997 , 39-57		1
63	The role of cytochrome P450 2D6 in the metabolism of moclobemide. <i>European Neuropsychopharmacology</i> , 1996 , 6, 225-30	1.2	17
62	Induction of c-fos gene expression by the selective sigma receptor ligand EMD 57445 in rat brain. <i>European Neuropsychopharmacology</i> , 1996 , 6, 237-43	1.2	17
61	Expression of alpha subunit genes of nicotinic acetylcholine receptors in human lymphocytes. <i>Neuroscience Letters</i> , 1996 , 214, 171-4	3.3	63
60	Psychosocial stress in tree shrews: clomipramine counteracts behavioral and endocrine changes. <i>Pharmacology Biochemistry and Behavior</i> , 1996 , 54, 219-28	3.9	141
59	Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT. <i>Psychopharmacology</i> , 1996 , 124, 285-7	4.7	26
58	Excretion of 2- and 3-monomethyl ethers of 2-hydroxyestrogens in healthy male volunteers. <i>European Journal of Endocrinology</i> , 1996 , 135, 193-7	6.5	3
57	Automated determination of dextromethorphan and its main metabolites in human plasma by high-performance liquid chromatography and column switching. <i>Therapeutic Drug Monitoring</i> , 1996 , 18, 297-303	3.2	26
56	Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. <i>Journal of Clinical Psychiatry</i> , 1996 , 57, 257-64	4.6	31
55	Diurnal variations of plasma interleukin-6 in man: methodological implications of continuous use of indwelling cannulae. <i>Annals of the New York Academy of Sciences</i> , 1995 , 762, 468-70	6.5	6

54	The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients. <i>Psychopharmacology</i> , 1995 , 117, 472-8	4.7	5
53	Circadian variations in antigen-specific proliferation of human T lymphocytes and correlation to cortisol production. <i>Psychoneuroendocrinology</i> , 1995 , 20, 335-42	5	31
52	Automated Determination of Trimipramine and N-Desmethyl-Trimipramine in Human Plasma or Serum by HPLC With On-Line Solid Phase Extraction. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1995 , 18, 3495-3505		13
51	Time course of the effects of steroid hormone deprivation elicited by ovariectomy or ovariectomy plus adrenalectomy on the affinity and density of GABA binding sites in distinct rat brain areas. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1995 , 103, 196-204	2.3	22
50	Non-competitive inhibition of clomipramine N-demethylation by fluvoxamine. <i>Psychopharmacology</i> , 1995 , 117, 149-53	4.7	16
49	Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. <i>Journal of Clinical Psychopharmacology</i> , 1995 , 15, 141-3	1.7	45
48	Interleukin-6 in plasma collected with an indwelling cannula reflects local, not systemic, concentrations. <i>Clinical Chemistry</i> , 1994 , 40, 1778-1779	5.5	27
47	Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in schizophrenic patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1994 , 102, 326-33	2.3	3
46	Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. <i>Psychopharmacology</i> , 1994 , 116, 457-63	4.7	2
45	Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. <i>Psychopharmacology</i> , 1994 , 116, 469-74	4.7	115
44	Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. <i>Journal of Psychiatric Research</i> , 1994 , 28, 461-73	5.2	50
43	Day- and nighttime content of monoamines and their metabolites in the pineal gland of rat and hamster. <i>Neuroscience Letters</i> , 1994 , 179, 119-22	3.3	14
42	Elevated Levels of Clozapine in Serum After Addition of Fluvoxamine. <i>Journal of Clinical Psychopharmacology</i> , 1994 , 14, 279-280	1.7	111
41	Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography. <i>Therapeutic Drug Monitoring</i> , 1994 , 16, 400-6	3.2	36
40	Elevated levels of clozapine in serum after addition of fluvoxamine. <i>Journal of Clinical Psychopharmacology</i> , 1994 , 14, 279-81	1.7	35
39	Interleukin-6 in plasma collected with an indwelling cannula reflects local, not systemic, concentrations. <i>Clinical Chemistry</i> , 1994 , 40, 1778-9	5.5	9
38	Monitoring tricyclic antidepressant concentrations in serum by fluorescence polarization immunoassay compared with gas chromatography and HPLC. <i>Clinical Chemistry</i> , 1994 , 40, 929-33	5.5	5
37	Simultaneous Automated Determination of Catecholamines, Serotonin, and Their Metabolites in Brain Tissue by HPLC and Electrochemical Detection. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1993 , 16, 447-463		14

36	Determination of Homovanillic Acid in Human Plasma Using HPLC with Electrochemical Detection and Automated Solid Phase Extraction. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1993 , 16, 2813-2823		6
35	Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. <i>Psychopharmacology</i> , 1993 , 110, 302-8	4.7	60
34	Drug Monitoring in Psychiatric Patients: Which Approach is Useful to Improve Psychopharmacotherapy?. <i>Pharmacopsychiatry</i> , 1992 , 25, 72-74	2	2
33	Actions of sex hormones on the brain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1992 , 16, 377-88	5.5	8
32	Sub-acute effects of interferon-alpha 2 on adrenocorticotrophic hormone, cortisol, growth hormone and prolactin in humans. <i>Psychoneuroendocrinology</i> , 1992 , 17, 459-65	5	26
31	Automated Determination of Fluvoxamine in Plasma by Column-Switching High-Performance Liquid Chromatography. <i>Clinical Chemistry</i> , 1992 , 38, 2082-2086	5.5	52
30	Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. <i>Biomedical Applications</i> , 1992 , 578, 273-82		34
29	Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. <i>Biomedical Applications</i> , 1992 , 583, 209-16		65
28	Relation between leukocyte counts and cortisol secretion in CML patients undergoing combined TNF alpha/IFN alpha therapy. <i>Annals of Hematology</i> , 1992 , 65, 116-20	3	
27	Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. <i>Clinical Chemistry</i> , 1992 , 38, 2082-6	5.5	13
26	Production of the Neurosteroid 3alpha-Hydroxy-5alpha-pregnan-20-one in Man. <i>Journal of Neuroendocrinology</i> , 1991 , 3, 261-5	3.8	6
25	Determination of benperidol and its reduced metabolite in human plasma by high-performance liquid chromatography and electrochemical detection. <i>Biomedical Applications</i> , 1991 , 565, 363-73		8
24	Evidence that 3 alpha-hydroxy-5 alpha-pregnan-20-one is a physiologically relevant modulator of GABA-ergic neurotransmission. <i>Psychoneuroendocrinology</i> , 1991 , 16, 517-23	5	17
23	Effects of ovariectomy and steroid replacement on GABAA receptor binding in female rat brain. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1991 , 38, 141-7	5.1	24
22	Interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man. <i>Neuroendocrinology</i> , 1991 , 54, 499-503	5.6	38
21	Sex differences in GABAA receptor binding in rat brain measured by an improved in vitro binding assay. <i>Experimental Brain Research</i> , 1990 , 81, 297-302	2.3	23
20	Formation and metabolism of catecholestrogens in depressed patients. <i>Biological Psychiatry</i> , 1990 , 28, 685-96	7.9	9
19	Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists. <i>Biochemical Pharmacology</i> , 1987 , 36, 3175-80	6	50

18	Improved model for the induction of proestrus-like gonadotropin surges in long-term ovariectomized rats. <i>The Journal of Steroid Biochemistry</i> , 1987 , 28, 357-9		7
17	Sex-specific effects of estradiol on hypothalamic noradrenaline turnover in gonadectomized rats. <i>Experimental Brain Research</i> , 1985 , 59, 68-72	2.3	12
16	Antioestrogen inhibition of oestradiol-induced alterations in hypothalamic noradrenaline turnover. <i>Journal of Endocrinology</i> , 1985 , 106, 37-42	4.7	5
15	Time-dependent effects of oestradiol and progesterone on hypothalamic catecholamine turnover in ovariectomized rats. <i>Journal of Endocrinology</i> , 1985 , 106, 303-9	4.7	9
14	Interaction of non-steroidal antiestrogens with dopamine receptor binding. <i>The Journal of Steroid Biochemistry</i> , 1984 , 21, 663-7		31
13	Preferential uptake of norepinephrine into dopaminergic terminals of a synaptosomal preparation from rat cerebral cortex. <i>Brain Research</i> , 1984 , 301, 149-52	3.7	12
12	Re-establishment of stimulatory estradiol effects on luteinizing hormone secretion in long term ovariectomized rats. <i>Brain Research</i> , 1984 , 294, 182-5	3.7	5
11	Competition by monophenolic estrogens and catecholestrogens for high-affinity uptake of [3H](-)-norepinephrine into synaptosomes from rat cerebral cortex and hypothalamus. <i>Brain Research</i> , 1983 , 277, 163-8	3.7	34
10	Do catecholestrogens interact with the in vitro binding of radioligands to catecholamine receptors?. <i>The Journal of Steroid Biochemistry</i> , 1983 , 19, 1469-74		7
9	Effects of oestradiol benzoate and progesterone on luteinizing hormone release and catecholamine turnover in the preoptic-hypothalamic brain area of ovariectomized rats. <i>Journal of Endocrinology</i> , 1983 , 97, 437-45	4.7	17
8	Distribution and properties of thiol S-methyltransferase in rat brain. <i>Journal of Neurochemistry</i> , 1983 , 40, 592-4	6	2
7	Effects of short-term exposure to catecholestrogens on catecholamine turnover in the preoptic-hypothalamic brain of ovariectomized rats. <i>Brain Research</i> , 1982 , 240, 295-301	3.7	14
6	The action of 5 alpha-dihydrotestosterone and antiandrogens on the activities of 5 alpha-reductase and 3 alpha-hydroxysteroid dehydrogenase in the pituitary gland of gonadectomized rats. <i>The Journal of Steroid Biochemistry</i> , 1982 , 16, 545-52		8
5	Subcellular distribution of 3 alpha-hydroxysteroid dehydrogenase and antiestrogen action on androgen-metabolizing enzymes in rat pituitary gland. <i>Journal of Neurochemistry</i> , 1982 , 38, 876-83	6	7
4	Gaschromatographische Untersuchungen biogener Amine in Form ihrer Acetyl-, Propionyl-, n-Butyryl-, iso-Butyryl- und Pivaloylderivate. <i>Chromatographia</i> , 1979 , 12, 226-230	2.1	4
3	Gas-liquid chromatographic properties of catecholamines, phenylethylamines and indolalkylamines as their propionyl derivatives. <i>Journal of Chromatography A</i> , 1978 , 153, 451-460	4.5	20
2	SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents 319-328		
1	Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders		1

